Back to search resultsSummaryRMgm-1582
|
||||||||||
*RMgm-1582| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption, Introduction of a transgene |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 27600503 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. berghei |
| Parent strain/line | P. berghei ANKA |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Rizopoulos Z, Matuschewski K, Haussig J. |
| Name Group/Department | Parasitology Unit |
| Name Institute | Max Planck Institute for Infection Biology |
| City | Berlin |
| Country | Germany |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-1582 |
| Principal name | alas(-) |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not tested |
| Fertilization and ookinete | Not different from wild type |
| Oocyst | Normal numbers of oocysts are formed. However, day 10 and 14 oocysts had a reduced size (`60%) compared to wild type oocysts. A large (~10-20-fold) reduction in the numbers of midgut-associated sporozoites was observed. No hemocoel or salivary gland sporozoites were detected. |
| Sporozoite | Normal numbers of oocysts are formed. However, day 10 and 14 oocysts had a reduced size (`60%) compared to wild type oocysts. A large (~10-20-fold) reduction in the numbers of midgut-associated sporozoites was observed. No hemocoel or salivary gland sporozoites were detected. |
| Liver stage | A large (~10-20-fold) reduction in the numbers of midgut-associated sporozoites was observed. No hemocoel or salivary gland sporozoites were detected. No mosquito transmission. See also additional information of the role of ALAS during liver stage development |
| Additional remarks phenotype | Mutant/mutation Phenotype Additional information Some results in this paper are different from other analyses of mutants lacking expression of ALAS. See mutant RMgm-924 that showed strongly reduced oocyst production and absence of liver stage development. |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PBANKA_1459200 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1246100 | ||||||||||||||||||||||||
| Gene product | delta-aminolevulinic acid synthetase | ||||||||||||||||||||||||
| Gene product: Alternative name | ALAS | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | Fragments of the 3’ and 5’ UTR were amplified from gDNA using gene-specific primers. First, 3’ fragments were cloned into the pBAT vector, following restriction digestion with HindIII and KpnI to generate an intermediate construct (pHEME-im). Then, the 5’ UTR fragment was digested with SacII and EcoRV and cloned into the respective SacII- and PvuII-linearized pHEME-im construct, thus removing the mCherry-3xMyc tag. Finally, the pHEME-ko vector was linearized with ScaI and SalI before transfection into P. berghei strain ANKA (wt) parasites. | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
Transgene: Mutant parasite expressing a transgene| top of page | |||||||||||||||||||
| Type and details of transgene | |||||||||||||||||||
| Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
| Transgene name | GFP | ||||||||||||||||||
| top of page | |||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||
| Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||
| Promoter of the selectable marker | pbdhfr | ||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||
| Additional remarks genetic modification | |||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||
| top of page | |||||||||||||||||||
| Other details transgene | |||||||||||||||||||
| top of page | |||||||||||||||||||
| Promoter | |||||||||||||||||||
| Gene Model of Parasite | PBANKA_0711900 | ||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_0818900 | ||||||||||||||||||
| Gene product | heat shock protein 70 | ||||||||||||||||||
| Gene product: Alternative name | HSP70 | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||
| 3'-UTR | |||||||||||||||||||
| Gene Model of Parasite | PBANKA_1340000 | ||||||||||||||||||
| Gene product | dihydrofolate synthase/folylpolyglutamate synthase, putative | ||||||||||||||||||
| Gene product: Alternative name | PbDHFS-FPGS | ||||||||||||||||||
| |||||||||||||||||||
| Insertion/Replacement locus | |||||||||||||||||||
| Replacement / Insertion | Replacement locus | ||||||||||||||||||
| Gene Model of Parasite | PBANKA_1459200 | ||||||||||||||||||
| Gene product | delta-aminolevulinic acid synthetase | ||||||||||||||||||
| Gene product: Alternative name | ALAS | ||||||||||||||||||
| |||||||||||||||||||
| top of page | |||||||||||||||||||